NEXT PHASE

By Nono Hu, Director of Marketing, LSN

On June 19, more than 600 healthcare entrepreneurs and investors entered the exhibition hall at the Westin San Diego Gaslamp Quarter. They were greeted by 30 Innovation Challenge finalists across therapeutics, medical device, diagnostics, and healthcare IT sectors. The 30 companies, hand selected by LSN’s scientific and commercial review team, competed directly on merits of innovation and commercial viability. Here, LSN would like to present the top 3 winners who attracted the greatest amount of “RESI Cash”.

First Place: Taithera

Taithera is redefining orthopaedics. Taithera is developing a first-in-class bone targeted drug delivery platform for the treatment of musculoskeletal disorders. The core of Taithera’s revolutionary platform is a nanoparticle that is programmed to deliver therapeutics directly to the site of a bone lesion. This hyper-targeted delivery platform can be used to treat primary and metastatic bone cancers, fractures, osteoporosis, and other bone conditions. Taithera is based in New York City, and was founded by Mo Chen, PhD and Seth Harlem.

Michael Quigley, VP of Market Research, Life Science Nation | Mo Chen, Co-Founder & Chief Science Officer, Taithera | Seth Harlem, Co-Founder & Chief Executive Officer, Taithera

Second Place: Tasso

Tasso is a medical device company that is developing the HemoLink, a user-friendly way to self-collect blood for clinical testing that has the potential to fundamentally change how people interface with healthcare. The HemoLink is a device that enables high-quality blood sample collection with one press of a button. After the blood draw is complete, the tube appended to the device simply twists off and can be used directly within standard lab processes. The HemoLink is enabled by novel microfluidic technologies that enable connectivity (e.g. tube types), simple low-cost manufacturing, and plasma separation onsite. The HemoLink can replace phlebotomy in small clinics and bring blood collection to the home.

Michael Quigley, VP of Market Research, Life Science Nation | Ben Casaavant, VP, Engineering, Tasso

Third Place: ViewsIQ

ViewsIQ is a medical technology company, digitizing patient samples microscopically to disrupt the pathology practice – the last remaining medical imaging field to go digital. ViewsIQ’s Panoptiq system is the first software-based approach to digital imaging that allows seamless integration into a Pathologist’s clinical workflow. With Panoptiq, the cost barrier to digital imaging has been removed, permitting clinicians to offer expert diagnostic care to patients virtually anywhere in the world.

Michael Quigley, VP of Market Research, Life Science Nation | Herman Lo, CEO, ViewsIQ

Thank you to all who competed in the RESI San Diego Innovation Challenge, and to all the RESI attendees who took part by investing their votes in their favorite competing companies.

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

When LSN decided to bring RESI to San Diego, we took note of the rhythm of other events and receptions that take place during BIO week. What did we see? A distinct lull on Monday. That’s the day when we kick off the week, and LSN saw an opportunity to fill that gap with partnering meetings and early stage focused content.

Adding a day full of meetings prior to BIO is sure to make your week more productive, more connected and more fruitful. And to keep you busy between meetings, RESI has 3 tracks of investor panels and early stage workshops to edify and advise you in your fundraising. If you’d like to join us there, it’s not too late – you can sign up now.

By Natasha Eldridge, RESI Conference Manager, LSN

How do you get the most out of a day of networking and one-to-one meetings? It’s all about being able to connect with the right partners. At RESI, hundreds of highly innovative early stage companies in drug development, medical devices, diagnostics and healthcare IT come to meet with hundreds of early stage investors focused on those verticals. RESI gathers attendees from not just all over North America, but all over the world. The investors in attendance are very diverse, representing both traditional funding sources like venture capital firms and large pharmas, and also newer sources in early stage investment such as family offices and nonprofit foundations. Via RESI’s uniquely curated Partnering system, attendees can zero in on the most relevant potential investors and ensure that their meetings will have a strong basis in mutual fit. Want to take part?

Register here now

By Lucy Parkinson, Director of Research, LSN

Genomic innovation cuts across many technology verticals.  The dawn of efficient and inexpensive gene sequencing enabled many breakthrough discoveries in biology by identifying genes that have a role in specific diseases. Patients can now be stratified by genetic subtypes in order to identify the most suitable treatment. Some startups aim to use sequencing to identify future health risks. Meanwhile, sequencing has created massive amounts of genetic data, which could yield many further discoveries with the right curation and analysis.

At RESI, a panel of investors with a focus on genomics will discuss what kind of breakthroughs they are looking to back, and what challenges still remain in the genomics field.

Moderated by Amanda Cashin (Head of Illumina Accelerator), the participants are:

• Beth Hill (Johnson & Johnson Innovation – JLABS)
• Jonathan Kabakoff (Alexandria Venture Investments)
• Ted Driscoll (Decheng Capital)
• François Ferré (ALMA Life Sciences)

By Nono Hu, Director of Marketing, LSN

With 10 days to go until the first RESI San Diego event, LSN is proud to present the latest RESI program guide. If you want to see the full lineup of sponsors, investor panelists, RESI Innovators and speakers, you’re in the right place. RESI San Diego will bring together hundreds of active investors and early stage startups to begin their BIO week with a dedicated day of partnering, networking, and early stage-focused content. Check out the details below.

By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

Life Science Nation (LSN) and Johnson and Johnson Innovation, JLABS have launched San Diego’s first Redefining Early Stage Investments (RESI) Conference on June 19th, 2017 during the 2017 BIO week when the biotech and medtech world gathers in San Diego. RESI San Diego will bring together 400+ fundraising CEOs and 400+ early stage investors (a 1:1 ratio) from around the globe, providing the opportunity for dialogue and relationship building, with the goal of eventual capital allocations. Register for RESI now.

By Lucy Parkinson, Director of Research, LSN

RESI is a venue where early stage life science startups can meet with investors of every type that are a fit for their company’s technology and stage – and that includes family offices. RESI San Diego features two panels devoted to this elusive investor class – Biotech Family Offices and Medtech Family Offices. Whether you’re developing a novel therapeutic, an innovative device or an improved diagnostic solution, Family Offices can’t be overlooked as a potential source of capital and RESI will provide you with the opportunity to hear advice and insight directly from key investment decision makers from family offices.

Biotech Family Offices, moderated by Colin Widen (CEO, Boston Innovation Capital), features:

• Jayson Rieger (SVP of Business Development & Portfolio Management, PBM Capital Group)
• Craig Philips (Partner, Whetstone Ventures)
• Sergei Petukhov (Partner, Enso Ventures)
• Chuck Stetson (CEO, Stetson Family Office)

Medtech Family Offices, moderated by Michael Quigley (VP of Market Research, Life Science Nation), features:

• Sean Kearney (Managing Director, Three Leaf Ventures)
• Julia Belaya (Director – Corporate Partnerships, Plug and Play Tech Center)
• John Kinzell (Senior Life Science Analyst, The McNair Group)
• Kyle Williams (President, Bootstrap Incubation)

To catch this rare opportunity to meet family office investors with a focus on early stage life science investment, register for RESI now.